New approaches to heart valve diseases in experimental and clinical cardiology
Authors:
J. Šochman 1; J. H. Peregrin 2
Authors‘ workplace:
Klinika kardiologie IKEM Přednosta: prof. MUDr. J. Kautzner, CSc.
1; Základna radiodiagnostiky a intervenční radiologie Přednosta: doc. MUDr. J. H. Peregrin, CSc.
Institut klinické a experimentální medicíny, Praha Ředitel: MUDr. Štefan Vítko, CSc.
2
Published in:
Prakt. Lék. 2006; 86(11): 635-642
Category:
Of different specialties
Overview
There has been a clear increase in the number of techniques in animal experiments dealing with various approaches to nonsurgical modification of heart valve diseases. It is also evident that some of the methods have already been put to use in clinical practice. This paper presents an overview of various options of the handling this issue and provides some morphological observations. It seems it is still too early to evaluate the different methods intended for a permanent solution to various cardiac valve defects. This is because relatively few procedures have been performed to date and, more importantly, nothing is known about the durability of the procedures. In addition, the standard of current cardiac surgery is very high. Still, it is quite easy to accept the idea for temporary catheter-based treatment of types of diseases currently not eligible for surgery, or in cases where surgery would be associated with unacceptably high risk.
Key words:
experimental methods, heart valve diseases, nonsurgical techniques
Labels
General practitioner for children and adolescents General practitioner for adultsArticle was published in
General Practitioner
2006 Issue 11
Most read in this issue
- Experience in the treatment of torpid condylomata acuminata by 5% imiquimod cream
- Anaemia in chronic heart failure
- Indications of allogeneic and autologous haematopoietic cells transplantation – Recommendations of the Czech Society of Haematology and Czech Society of Oncology of the J. E. Purkyně Czech Medical Association.
- Valganciclovir in the pre-emptive treatment of cytomegalovirus infections following allogeneic stem cell transplantation.